Pharmaceutical - Financial, Forest Laboratories


Popular Filters

Forest Labs sales top analysts’ forecasts


US drugmaker Forest Laboratories, currently the subject of a takeover by Actavis, has reported diluted…

FinancialForest LaboratoriesPharmaceutical

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration


Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable


Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations


US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Adamas Pharma earns $40 milestone in Forest deal


California, USA-based Adamas Pharmaceuticals revealed yesterday (January 9) that it has received $40…

Adamas PharmaceuticalsdonepezilFinancialForest LaboratoriesMDX-8704NamendaNeurologicalPharmaceuticalResearch

Forest spends $240 million for US rights to Saphris; streamlines operations


US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

Forest Labs reports rise in sales and EPS doubles in second quarter results


Forest Laboratories has released its second quarter results which showed that net sales for the quarter…

BystolicCNS DiseasesDalirespFinancialForest LaboratoriesLinzessNamendaNorth AmericaPharmaceuticalRespiratory and PulmonarySavellaTeflaroTudorza PressairViibryd

Forest Labs names new CEO to replace Howard Solomon


US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September…

BoardroomFinancialForest LaboratoriesNorth AmericaPharmaceutical

Forest Labs 1st-qtr profit slumps 53%, on charges, Lexapro competition


US drugmaker Forest Labs (NYSE:FRX) has reported fiscal 2013/14 first quarter (ended June 30) profit…

FinancialForest LaboratoriesPharmaceutical

Trevena and Forest Labs collaborate on TRV027 for acute heart failure


US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Forest Labs' profit slumps 76% on Lexapro patent loss


US drugmaker Forest Laboratories (NYSE: FRX) posted fiscal fourth-quarter (ended March 31, 2013) profit…

FinancialForest LaboratoriesLexaproPharmaceutical

Drugmakers to continue facing growing generic competition in 2013


Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Forest Labs posts third-quarter loss, hit by Lexapro sales slump


US drugmaker Forest Laboratories (NYE: FRX) saw its shares fall 5.6% to $35.39 in pre-market trading…

FinancialForest LaboratoriesPharmaceutical

Forest Labs' second fiscal quarter sales and earnings plummet


US drugmaker Forest Laboratories (NYSE: FRX) reported GAAP earnings per share of $0.08 in the second…

FinancialForest LaboratoriesPharmaceutical

Forest Lab's earnings plunge 79%, hit by generic Lexapro


US drugmaker Forest Laboratories (Nasdaq: FRX) yesterday reported that net income for the quarter ended…

FinancialForest LaboratoriesLexaproPharmaceutical

Forest Labs cuts FY 2013 earnings forecasts on Lexapro woes


Following the expiration of US drugmaker Forest Laboratories' (NYSE: FRX) once best-selling anxiety drug…

FinancialForest LaboratoriesGenericsLevothroidLexaproPharmaceutical

Forest Labs profit plunges as Lexapro loses patent


US drugmaker Forest Laboratories (NYSE: FRX) that reported earnings per share equaled $0.72 in the fourth…

FinancialForest LaboratoriesPharmaceutical

Forest Labs EPS beat consensus forecasts


US drugmaker Forest Laboratories (NYSE: FRX) has reported earnings per share of $1.04 for its third fiscal…

FinancialForest LaboratoriesPharmaceutical

Back to top